<DOC>
	<DOCNO>NCT01154543</DOCNO>
	<brief_summary>To determine efficacy Famvir 500mg bd suppressive antiviral therapy acute genital Herpes simplex virus ( HSV ) outbreaks HIV subject .</brief_summary>
	<brief_title>Safety Efficacy Famciclovir HIV1 Positive Adults With Recurrent Genital Herpes</brief_title>
	<detailed_description />
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<criteria>Able provide sign informed consent Documented HIV infection In general good health , without serious medical condition deem investigator Male female 18 year age Diagnosed genital HSV ( clinical laboratory ) Life expectancy 12 month long per investigator 's judgment Stable Famvir 500 mg bd least 30 day time screen Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 ) mIU/mL ) . Women childbearing potential unwilling use reliable contraception duration study . History hypersensitivity Famvir , constituent penciclovir Current use another antiherpetic medication Recent history alcohol drug abuse , opinion investigator may interfere compliance study requirement , condition opinion investigator would interfere successful completion study procedure Disorder condition could interfere drug absorption , distribution , metabolism excretion Known suspect past history renal dysfunction require dosage modification Famvir 500 bd</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Recurrent genital Herpes Simplex Virus</keyword>
</DOC>